N
News Analysis
prnewswire.com

www.prnewswire.com ·

Negative

keenova reports first quarter 2026 financial results 302769401

EPU_POLICY_POLICYCRISISLEX_C03_WELLBEING_HEALTHECON_STOCKMARKETMANMADE_DISASTER_IMPLIED

Topic context

This topic has been covered 349429 times in the last 30 days across our monitored publishers.

Related topics

TeknolojiMarketsSpor

All NewsRead the full story on prnewswire.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Keenova Therapeutics reported strong Q1 2026 results driven by Acthar Gel and XIAFLEX sales growth. The company is on track to realize merger synergies. No specific supply chain or commodity price impacts are mentioned; the news is company-specific and does not indicate broader sector-wide commercial mechanisms.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Net sales from continuing operations $468M, up $261M YoY
  • Acthar Gel sales $170M, up 47%
  • XIAFLEX sales $134M
  • Loss from continuing operations $114M
  • Adjusted EBITDA $174M; 2026 guidance reaffirmed: net sales $1.94B-$2.00B, adjusted EBITDA $730M-$760M

Related stories

finance.yahoo.com

zillow zg q1 2026 earnings 225404880

finance.yahoo.com

stock surge robust tech earnings 203703879

mondaq.com:443

weekly sanctions update may 4 2026

pharmiweb.com

celanese corporation reports first quarter earnings

abc.net.au

mouse plague morawa health fears

About the publisher

prnewswire.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

Coverage of incidents involving fatalities. Numbers and causes are taken from primary reporting.

keenova reports first quarter 2026 financial results 302769401 | prnewswire.com — News Analysis